PL2627319T3 - Kompozycje farmaceutyczne zawierające inhibitor DGAT1 - Google Patents

Kompozycje farmaceutyczne zawierające inhibitor DGAT1

Info

Publication number: PL2627319T3
Authority: PL; Poland
Prior art keywords: pharmaceutical compositions; compositions containing; dgat1 inhibitor; dgat1; inhibitor
Prior art date: 2010-10-14

Application number

PL11779278T

Other languages

English (en)

Inventor

Hong Wen

Natrajan Kumaraperumal

Richard Nause

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-14

Filing date

2011-10-14

Publication date

2019-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44908106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2627319(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-14 Application filed by Novartis Ag filed Critical Novartis Ag

2019-05-31 Publication of PL2627319T3 publication Critical patent/PL2627319T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

PL11779278T 2010-10-14 2011-10-14 Kompozycje farmaceutyczne zawierające inhibitor DGAT1 PL2627319T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39310310P	2010-10-14	2010-10-14
PCT/US2011/056275 WO2012051488A1 (en)	2010-10-14	2011-10-14	Pharmaceutical compositions containing a dgat1 inhibitor
EP11779278.8A EP2627319B1 (en)	2010-10-14	2011-10-14	Pharmaceutical compositions containing a dgat1 inhibitor

Publications (1)

Publication Number	Publication Date
PL2627319T3 true PL2627319T3 (pl)	2019-05-31

Family

ID=44908106

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11779278T PL2627319T3 (pl)	2010-10-14	2011-10-14	Kompozycje farmaceutyczne zawierające inhibitor DGAT1

Country Status (30)

Country	Link
US (5)	US20130190354A1 (pl)
EP (1)	EP2627319B1 (pl)
JP (1)	JP6060081B2 (pl)
KR (1)	KR20130100311A (pl)
CN (1)	CN103179957B (pl)
AR (1)	AR083417A1 (pl)
AU (1)	AU2011316003B2 (pl)
BR (1)	BR112013008757A2 (pl)
CA (1)	CA2813781C (pl)
CL (1)	CL2013001001A1 (pl)
CO (1)	CO6710915A2 (pl)
DK (1)	DK2627319T3 (pl)
EC (1)	ECSP13012755A (pl)
ES (1)	ES2712064T3 (pl)
GT (1)	GT201300096A (pl)
HU (1)	HUE043524T2 (pl)
IL (1)	IL225434A0 (pl)
MA (1)	MA34599B1 (pl)
MX (1)	MX2013004162A (pl)
NZ (1)	NZ608558A (pl)
PE (1)	PE20140375A1 (pl)
PH (1)	PH12013500695A1 (pl)
PL (1)	PL2627319T3 (pl)
PT (1)	PT2627319T (pl)
RU (1)	RU2595866C2 (pl)
SG (1)	SG189078A1 (pl)
SI (1)	SI2627319T1 (pl)
TR (1)	TR201902435T4 (pl)
WO (1)	WO2012051488A1 (pl)
ZA (1)	ZA201302108B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR083417A1 (es)	2010-10-14	2013-02-21	Novartis Ag	Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013163508A1 (en) *	2012-04-27	2013-10-31	Novartis Ag	Tetrahydropyran dgat1 inhibitors
WO2013169648A1 (en) *	2012-05-07	2013-11-14	Novartis Ag	Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
EP3267989A4 (en)	2015-03-13	2018-11-07	Esperion Therapeutics, Inc.	Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017084234A1 (zh) *	2015-11-19	2017-05-26	欣耀生医股份有限公司	预防或治疗脂肪肝的药物组合物
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
EP3424505A4 (en)	2016-03-04	2019-10-16	Taiho Pharmaceutical Co., Ltd.	PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US20180338922A1 (en) *	2017-05-26	2018-11-29	Esperion Therapeutics, Inc.	Fixed dose formulations
WO2019046659A1 (en) *	2017-08-30	2019-03-07	First Fruits Business Ministry, Llc	COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
EA202092190A1 (ru)	2018-03-16	2020-11-19	Анджи Фармасьютикалз Инк.	Композиции и способы для лечения сильного запора
JP6918204B2 (ja)	2018-03-19	2021-08-11	大鵬薬品工業株式会社	アルキル硫酸ナトリウムを含む医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69633018T2 (de)	1995-11-14	2004-12-09	Abbott Gmbh & Co. Kg	Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
GB9613470D0 (en)	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
DE19816070A1 (de)	1998-04-09	1999-10-14	Aventis Res & Tech Gmbh & Co	Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
PL371259A1 (pl) *	2001-12-21	2005-06-13	Pfizer Products Inc.	Bezpośrednio sprasowywalne preparaty azytromycyny
WO2006113919A2 (en) *	2005-04-19	2006-10-26	Bayer Pharmaceuticals Corporation	Aryl alkyl acid derivatives for and use thereof
KR101219042B1 (ko) *	2005-12-06	2013-01-07	삼성디스플레이 주식회사	반투과형 액정 표시 장치
CA2633167A1 (en)	2005-12-16	2007-07-12	Merck & Co., Inc.	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
AR059739A1 (es) *	2006-03-06	2008-04-23	Wyeth Corp	Formulaciones y procesos para tabletas
US20070224258A1 (en) *	2006-03-22	2007-09-27	Bunick Frank J	Dosage forms having a randomized coating
EP2418202B1 (en) *	2006-03-31	2014-01-29	Novartis AG	(4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
CN101636155A (zh)	2006-11-29	2010-01-27	艾博特公司	二酰甘油o-酰基转移酶1型酶的抑制剂
US20080145425A1 (en) *	2006-12-15	2008-06-19	Pliva Research & Development Limited	Pharmaceutical composition of zolpidem
NZ580660A (en)	2007-04-30	2012-02-24	Abbott Lab	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US8283331B2 (en) *	2007-10-09	2012-10-09	Children's Medical Center Corporation	Methods to regulate miRNA processing by targeting Lin-28
WO2010114801A1 (en) *	2009-03-31	2010-10-07	Ligand Pharmaceuticals Inc.	Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
NZ602125A (en) *	2010-03-30	2014-01-31	Novartis Ag	Uses of dgat1 inhibitors
AR083417A1 (es)	2010-10-14	2013-02-21	Novartis Ag	Composiciones farmaceuticas que contienen un dgat1 inhibidor

2011
- 2011-10-13 AR ARP110103797A patent/AR083417A1/es unknown
- 2011-10-14 CA CA2813781A patent/CA2813781C/en active Active
- 2011-10-14 US US13/825,919 patent/US20130190354A1/en not_active Abandoned
- 2011-10-14 PT PT11779278T patent/PT2627319T/pt unknown
- 2011-10-14 BR BR112013008757-9A patent/BR112013008757A2/pt not_active IP Right Cessation
- 2011-10-14 MA MA35806A patent/MA34599B1/fr unknown
- 2011-10-14 SI SI201131677T patent/SI2627319T1/sl unknown
- 2011-10-14 RU RU2013121795/15A patent/RU2595866C2/ru active
- 2011-10-14 PE PE2013000837A patent/PE20140375A1/es not_active Application Discontinuation
- 2011-10-14 NZ NZ608558A patent/NZ608558A/en not_active IP Right Cessation
- 2011-10-14 DK DK11779278.8T patent/DK2627319T3/en active
- 2011-10-14 ES ES11779278T patent/ES2712064T3/es active Active
- 2011-10-14 TR TR2019/02435T patent/TR201902435T4/tr unknown
- 2011-10-14 JP JP2013534025A patent/JP6060081B2/ja active Active
- 2011-10-14 WO PCT/US2011/056275 patent/WO2012051488A1/en not_active Ceased
- 2011-10-14 AU AU2011316003A patent/AU2011316003B2/en not_active Ceased
- 2011-10-14 EP EP11779278.8A patent/EP2627319B1/en active Active
- 2011-10-14 MX MX2013004162A patent/MX2013004162A/es not_active Application Discontinuation
- 2011-10-14 PL PL11779278T patent/PL2627319T3/pl unknown
- 2011-10-14 KR KR1020137009333A patent/KR20130100311A/ko not_active Withdrawn
- 2011-10-14 HU HUE11779278A patent/HUE043524T2/hu unknown
- 2011-10-14 CN CN201180049179.4A patent/CN103179957B/zh active Active
- 2011-10-14 PH PH1/2013/500695A patent/PH12013500695A1/en unknown
- 2011-10-14 SG SG2013021944A patent/SG189078A1/en unknown
2013
- 2013-03-20 ZA ZA2013/02108A patent/ZA201302108B/en unknown
- 2013-03-21 IL IL225434A patent/IL225434A0/en unknown
- 2013-04-11 CO CO13094273A patent/CO6710915A2/es not_active Application Discontinuation
- 2013-04-11 GT GT201300096A patent/GT201300096A/es unknown
- 2013-04-12 CL CL2013001001A patent/CL2013001001A1/es unknown
- 2013-04-12 EC ECSP13012755 patent/ECSP13012755A/es unknown
2015
- 2015-07-22 US US14/805,919 patent/US20150320687A1/en not_active Abandoned
2016
- 2016-09-12 US US15/262,056 patent/US20160374947A1/en not_active Abandoned
2018
- 2018-05-01 US US15/968,104 patent/US10646446B2/en active Active
2020
- 2020-03-31 US US16/835,921 patent/US11304907B2/en active Active

Also Published As

Publication number	Publication date
US20150320687A1 (en)	2015-11-12
RU2013121795A (ru)	2014-11-20
CA2813781C (en)	2018-08-07
ZA201302108B (en)	2013-11-27
IL225434A0 (en)	2013-06-27
TR201902435T4 (tr)	2019-03-21
HUE043524T2 (hu)	2019-08-28
GT201300096A (es)	2014-07-08
JP6060081B2 (ja)	2017-01-11
SI2627319T1 (sl)	2019-04-30
CN103179957A (zh)	2013-06-26
KR20130100311A (ko)	2013-09-10
WO2012051488A1 (en)	2012-04-19
JP2013539794A (ja)	2013-10-28
US11304907B2 (en)	2022-04-19
AR083417A1 (es)	2013-02-21
US20200230062A1 (en)	2020-07-23
MA34599B1 (fr)	2013-10-02
US20130190354A1 (en)	2013-07-25
CN103179957B (zh)	2016-05-18
BR112013008757A2 (pt)	2020-09-01
CO6710915A2 (es)	2013-07-15
US10646446B2 (en)	2020-05-12
US20160374947A1 (en)	2016-12-29
SG189078A1 (en)	2013-05-31
AU2011316003A1 (en)	2013-04-11
CA2813781A1 (en)	2012-04-19
ECSP13012755A (es)	2014-01-31
EP2627319B1 (en)	2018-11-21
ES2712064T3 (es)	2019-05-09
PE20140375A1 (es)	2014-03-19
MX2013004162A (es)	2014-12-08
PH12013500695A1 (en)	2017-08-09
NZ608558A (en)	2015-03-27
US20180243222A1 (en)	2018-08-30
CL2013001001A1 (es)	2013-10-25
AU2011316003B2 (en)	2015-03-19
DK2627319T3 (en)	2019-03-18
PT2627319T (pt)	2019-02-27
EP2627319A1 (en)	2013-08-21
RU2595866C2 (ru)	2016-08-27

Publication	Publication Date	Title
ZA201302108B (en)	2013-11-27	Pharmaceutical compositions containing a dgat1 inhibitor
ZA201300458B (en)	2013-09-25	C-met-modulator pharmaceutical compositions
IL221164A0 (en)	2012-09-24	Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
ZA201301766B (en)	2016-11-30	Pharmaceutical compositions
IL247079A0 (en)	2016-09-29	A rapidly dissolving pharmaceutical compound
ZA201207670B (en)	2013-05-29	Pharmaceutical compositions
GB201008005D0 (en)	2010-06-30	Pharmaceutical compounds
ZA201207839B (en)	2013-06-26	Pharmaceutical composition comprising a pyrimidineone derivative
ZA201300718B (en)	2013-08-28	Pharmaceutical compositions
ZA201304633B (en)	2014-03-26	A pharmaceutical composition
ZA201203012B (en)	2012-12-27	Solid pharmaceutical compositions containing an intergrase inhibitor
PL2552403T3 (pl)	2016-01-29	Szybko rozpuszczająca się kompozycja farmaceutyczna
ZA201303223B (en)	2014-01-29	Pharmaceutical compositions
GB201020161D0 (en)	2011-01-12	Pharmaceutical compounds
ZA201101850B (en)	2012-11-28	Composition having a sirtuin activator
ZA201303177B (en)	2018-12-19	Pharmaceutical compositions
EP2560678A4 (en)	2013-09-18	PHARMACEUTICAL COMPOSITIONS
ZA201201003B (en)	2012-10-31	A pharmaceutical composition
ZA201202951B (en)	2012-12-27	Pharmaceutical composition containing a phenocarbamate acetylcholinesterase inhibitor
GB201002162D0 (en)	2010-03-31	Packaging thirty three a
GB201004308D0 (en)	2010-04-28	New inhibitor compounds
ZA201303732B (en)	2018-12-19	Pharmaceutical compositions
GB201008590D0 (en)	2010-07-07	Pharmaceutical compositions
IL223324A0 (en)	2013-02-03	Novel pharmaceutical compounds
GB201013968D0 (en)	2010-10-06	Pharmaceutical compounds